Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate

MT Newswires Live

Jun 03

Nyrada (ASX:NYR) completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.

The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.

Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.

The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.

The company's shares fell 6% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2640973230"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640973230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640973230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640973230","market":"sh","top_or_hot":-1,"title":"Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.</p><p>The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.</p><p>Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.</p><p>The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.</p><p>The company's shares fell 6% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 12:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.</p><p>The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.</p><p>Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.</p><p>The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.</p><p>The company's shares fell 6% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640973230","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640973230","pubTimestamp":1780460646,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.The company's shares fell 6% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NYR.AU":"NYRADA INC-CDI","DBB":"基础金属ETF-PowerShares"},"translate_title":"Nyrada完成主要候选药物的心脏保护试点研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBB":1.5,"NYR.AU":1},"content_text":"Nyrada (ASX:NYR) completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.The company's shares fell 6% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}